Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
Journal for ImmunoTherapy of Cancer · 2023-08 · 11 (8) · e007336
DOI: 10.1136/jitc-2023-007336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 16.08.2023. Verfasst von Renato Brito Baleeiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers and Biotherapeutics, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Oncolytic Viruses. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Cancer Research UK.
Abstract (Originalsprache)
Background
Triple-negative breast cancer (TNBC) corresponds to approximately 20% of all breast tumors, with a high propensity for metastasis and a poor prognosis. Because TNBC displays a high mutational load compared with other breast cancer types, a neoantigen-based immunotherapy strategy could be effective. One major bottleneck in the development of a neoantigen-based vaccine for TNBC is the selection of the best targets, that is, tumor-specific neoantigens which are presented at the surface of tumor cells and capable of eliciting robust immune responses. In this study, we aimed to set up a platform for identification and delivery of immunogenic neoantigens in a vaccine regimen for TNBC using oncolytic vaccinia virus (VV).
Methods
We used bioinformatic tools and cell-based assays to identify immunogenic neoantigens in TNBC patients’ samples, human and murine cell lines. Immunogenicity of the neoantigens was tested in vitro (human) and ex vivo (murine) in T-cell assays. To assess the efficacy of our regimen, we used a preclinical model of TNBC where we treated tumor-bearing mice with neoantigens together with oncolytic VV and evaluated the effect on induction of neoantigen-specific CD8+T cells, tumor growth and survival.
Results
We successfully identified immunogenic neoantigens and generated neoantigen-specific CD8+T cells capable of recognizing a human TNBC cell line expressing the mutated gene. Using a preclinical model of TNBC, we showed that our tumor-specific oncolytic VV was able to change the tumor microenvironment, attracting and maintaining mature cross-presenting CD8α+dendritic cells and effector T-cells. Moreover, when delivered in a prime/boost regimen together with oncolytic VV, long peptides encompassing neoantigens were able to induce neoantigen-specific CD8+T cells, slow tumor growth and increase survival.
Conclusions
Our study provides a promising approach for the development of neoantigen-based immunotherapies for TNBC. By identifying immunogenic neoantigens and developing a delivery system through tumor-specific oncolytic VV, we have demonstrated that neoantigen-based vaccines could be effective in inducing neoantigen-specific CD8+T cells response with significant impact on tumor growth. Further studies are needed to determine the safety and efficacy of this approach in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Cancer Biomarkers and Biotherapeutics, Queen Mary University of London, London, UK.
- Department of Dermatology, Venerology and Allergology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Zhengzhou University, Zhengzhou, Henan, China.
- Centre for Cancer Biomarkers and Biotherapeutics, Queen Mary University of London, London, UK yaohe.wang@qmul.ac.uk.
ORCID-Profile: Renato Brito Baleeiro, Lauren Cutmore, Lydon Wainaina Nyambura, Yaohe Wang
Förderung
- Wellcome Trust
- Medical Research Council
- Cancer Research UK
- Breast Cancer Now
Zitieren
APA
Brito Baleeiro, R., Liu, P., Chard Dunmall, L. S., Di Gioia, C., Nagano, A., Cutmore, L., Wang, J., Chelala, C., Nyambura, L. W., Walden, P., Lemoine, N., & Wang, Y. (2023). Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer. Journal for ImmunoTherapy of Cancer, 11(8), e007336. https://doi.org/10.1136/jitc-2023-007336
Vancouver
Brito Baleeiro R, Liu P, Chard Dunmall LS, Di Gioia C, Nagano A, Cutmore L, et al. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 2023;11(8):e007336. doi:10.1136/jitc-2023-007336
BibTeX
@article{BritoBaleeiro2023,
author = {Brito Baleeiro, Renato and Liu, Peng and Chard Dunmall, Louisa S and Di Gioia, Carmela and Nagano, Ai and Cutmore, Lauren and Wang, Jun and Chelala, Claude and Nyambura, Lydon Wainaina and Walden, Peter and Lemoine, Nicholas and Wang, Yaohe},
title = {Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {8},
pages = {e007336},
doi = {10.1136/jitc-2023-007336}
}
EUVIMED